Philadelphia, PANCT04929236Now EnrollingIRB Ready

Chronic Inflammatory Demyelinating Polyradiculoneuropathy Clinical Trial in Philadelphia, PA

Access cutting-edge chronic inflammatory demyelinating polyradiculoneuropathy treatment through this phase 3 clinical trial at a research site in Philadelphia. Study-provided care at no cost to qualified participants.

Sponsored by Octapharma

Quick Self-Assessment

See if you qualify for this Philadelphia location

Preparing your pre-screening questions…

Expert Care in Philadelphia

Access chronic inflammatory demyelinating polyradiculoneuropathy specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related chronic inflammatory demyelinating polyradiculoneuropathy treatment provided free

Apply for This Philadelphia Location

Check if you qualify for this chronic inflammatory demyelinating polyradiculoneuropathy clinical trial in Philadelphia, PA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Philadelphia

    Convenient for PA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Philadelphia site if eligible
  4. 4Begin participation

About This Chronic Inflammatory Demyelinating Polyradiculoneuropathy Study in Philadelphia

Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients

Sponsor: Octapharma

Who Can Participate

Inclusion Criteria

Age ≥2 years and ≤17 years.
Patients with a diagnosis of CIDP based on European Academy of Neurology/Peripheral Nerve Society (EANPNS) 2021 guidelone \[1\]
Clinical history of functional impairment due to CIDP, corresponding to an mRS score ≥2, but ≤5.
Voluntarily given written informed consent (provided by patient's parent or legal guardian) and assent (provided by the patient, if age appropriate per Independent Ethics Committee \[IEC\]/Institutional Research Board \[IRB\] requirements).

Exclusion Criteria

Patients with previously diagnosed CIDP who lack any CIDP symptoms.
Patients with a known history of inherited neuropathy or a family history of inherited neuropathy.
Patients who have previously failed immunoglobulin therapy for CIDP.
Patients who received immunoglobulin or plasma exchange (PEX) within eight weeks prior to the Baseline Visit (washout phase). However, if a patient has clinical evidence of confirmed CIDP relapse during the washout phase (consistent with an increase in mRS of ≥1), they are eligible for trial enrolment.
Patients with a history of deep vein thrombosis (DVT) in the past year, or pulmonary embolism ever.
Patients on unstable (change in prescribed dose within the last eight weeks) corticosteroids or rituximab use.
Patients with known or suspected hypersensitivity, anaphylaxis, or severe systemic response to immune-globulins, blood or plasma derived products, or any component of PANZYGA.
Female patients who are breastfeeding, pregnant, or planning to become pregnant, or are unwilling to use an effective birth control method while on the study (acceptable methods of birth control for this study include: intrauterine device \[IUD\], hormonal contraception, male or female condom, spermicide gel, diaphragm, sponge, or cervical cap).
Presence of medical history information or clinical symptoms suggestive of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and/or hepatitis C virus (HCV) infections.
Severe liver and/or kidney disease (alanine aminotransferase \[ALT\] \> 3 × upper limit of normal \[ULN\]; aspartate aminotransferase \[AST\] \> 3 × ULN; and/or creatinine levels \>44 µmol/L for children ages 2-3 years, \>62 µmol/L for children ages 4-10 years, and \>89 µmol/L for children ages 11-17 years.
Presence of medical history information or clinical symptoms suggestive of immunoglobulin (IgA) deficiency and antibodies against IgA.
History of alcohol or drug abuse in the previous year, per Investigator's opinion.
Unable or unwilling to comply with the study protocol.
Receipt of any other investigational medicinal product (IMP) within three months before study entry or participating in another interventional clinical study. Prior participation in an observational or open-label study involving an approved product may be allowed but require prior consultation with the Medical Monitor to assess eligibilty.
Any other condition(s) that, in the Investigator's opinion, makes it undesirable for the patient to participate in the study or may interfere with protocol compliance.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Philadelphia?

Yes, this clinical trial (NCT04929236) has an active research site in Philadelphia, PA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Chronic Inflammatory Demyelinating Polyradiculoneuropathy Treatment Options in Philadelphia, PA

If you're searching for chronic inflammatory demyelinating polyradiculoneuropathy treatment options in Philadelphia, PA, this clinical trial (NCT04929236) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Philadelphia research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced chronic inflammatory demyelinating polyradiculoneuropathy specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all chronic inflammatory demyelinating polyradiculoneuropathy clinical trials near you to find additional studies recruiting in your area.

More Multiple Myeloma Trials in Philadelphia, PA

See all multiple myeloma clinical trials recruiting in Philadelphia — not just this study.

Browse Multiple Myeloma Trials in Philadelphia →

Browse More Trials by Condition

Multiple Myeloma TrialsFollicular Lymphoma TrialsAlzheimers Disease TrialsNeuropathy TrialsRheumatoid Arthritis TrialsAtopic Dermatitis TrialsInterstitial Cystitis TrialsAll Conditions →

Ready to Join in Philadelphia?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Philadelphia, PA